EP2394659B1 - Compositions et procédés pour le diagnostic, le traitement et la prévention des cancers répondant à l'hormone de croissance - Google Patents

Compositions et procédés pour le diagnostic, le traitement et la prévention des cancers répondant à l'hormone de croissance Download PDF

Info

Publication number
EP2394659B1
EP2394659B1 EP10184646.7A EP10184646A EP2394659B1 EP 2394659 B1 EP2394659 B1 EP 2394659B1 EP 10184646 A EP10184646 A EP 10184646A EP 2394659 B1 EP2394659 B1 EP 2394659B1
Authority
EP
European Patent Office
Prior art keywords
serum
cells
steroid hormone
cell
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP10184646.7A
Other languages
German (de)
English (en)
Other versions
EP2394659A1 (fr
Inventor
David A. Sirbasku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signe BioPharma Inc
Original Assignee
Signe BioPharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signe BioPharma Inc filed Critical Signe BioPharma Inc
Publication of EP2394659A1 publication Critical patent/EP2394659A1/fr
Application granted granted Critical
Publication of EP2394659B1 publication Critical patent/EP2394659B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0631—Mammary cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Claims (15)

  1. Composition de sérum de contrôle négatif comprenant:
    au moins une immunoglobuline sécrétoire choisie dans le groupe constitué de IgA, IgM et IgG sous une forme inactivée par rapport à la capacité d'inhiber la prolifération de cellules sensibles aux hormones stéroïdes en l'absence d'hormones stéroïdes; et
    un plasma sanguin appauvri en hormones stéroïdes ou un sérum sanguin appauvri en hormones stéroïdes.
  2. Composition de sérum de contrôle négatif selon la revendication 1, dans laquelle ladite au moins une immunoglobuline sécrétoire est inactivée en chauffant ledit plasma ou sérum sanguin appauvri en hormones stéroïdes contenant l'inhibiteur à base d'immunoglobuline à environ 50-60°C pendant une période de temps suffisante pour rendre l'inhibiteur inactif par rapport à la capacité d'inhiber la croissance de cellules cancéreuses sensibles aux hormones stéroïdes in vitro.
  3. Composition de sérum de contrôle négatif selon la revendication 2, dans laquelle la période de temps est entre environ 90 minutes et environ 30 h.
  4. Composition de sérum de contrôle négatif selon la revendication 1, dans laquelle ladite au moins une immunoglobuline sécrétoire est inactivée par:
    l'obtention d'un échantillon de sérum frais ou congelé non inactivé thermiquement;
    la réalisation d'une première extraction par charbon actif-dextrane sur l'échantillon à environ 30-37°C pour donner un premier sérum extrait; et
    la réalisation d'une deuxième extraction par charbon actif-dextrane à 30-37°C sur le premier sérum extrait pour donner un sérum appauvri en hormones stéroïdes ayant une activité réversible par des hormones stéroïdes d'inhibition de la croissance de cellules cancéreuses sensibles aux hormones stéroïdes.
  5. Composition de sérum de contrôle négatif selon la revendication 1, dans laquelle ladite au moins une immunoglobuline sécrétoire est inactivée par:
    la réalisation d'une extraction par résine échangeuse d'ions XAD™ d'un sérum frais ou congelé non inactivé thermiquement pour donner un sérum appauvri en hormones stéroïdes ayant une activité réversible par des hormones stéroïdes pour l'inhibition de la croissance de cellules cancéreuses sensibles aux hormones stéroïdes.
  6. Composition de sérum de contrôle négatif selon la revendication 1 pour une utilisation dans un test de prolifération de cellules cancéreuses.
  7. Sérum de contrôle négatif selon la revendication 1, dans lequel ladite au moins une immunoglobuline sécrétoire est sous une forme inactivée en l'absence d'une quantité réactivatrice de calcium.
  8. Kit de test pour la détection in vitro de la croissance de cellules sensibles aux hormones stéroïdes réversible par des hormones stéroïdes comprenant:
    une population de cellules cancéreuses sensibles aux hormones stéroïdes cultivées qui sont aussi sensibles aux hormones stéroïdes pour une prolifération in vivo;
    un milieu de culture de cellules nutritives défini sans sérum comprenant un fluide nutritif basal substantiellement dénué de Fe (III) non lié et contenant l'ion calcium;
    un inhibiteur à base d'immunoglobuline choisie dans le groupe constitué de IgA, IgM et IgG.
  9. Kit selon la revendication 8, comprenant en outre:
    au moins un additif de test choisi dans le groupe constitué d'hormones stéroïdes et des agonistes et des antagonistes de celles-ci.
  10. Kit selon la revendication 8 ou 9, dans lequel les cellules cancéreuses sensibles aux hormones stéroïdes sont des cellules tumorales mammaires de rat MTW9/PL2.
  11. Kit selon les revendications 8-10, dans lequel l'inhibiteur à base d'immunoglobuline est fourni dans un plasma sanguin appauvri en hormones stéroïdes ou un sérum sanguin appauvri en hormones stéroïdes tel que préparé dans l'une quelconque des revendications 2-5.
  12. Procédé pour la mesure de la quantité d'inhibiteur réversible par des hormones stéroïdes de la croissance de cellules sensibles aux hormones stéroïdes dans un échantillon de fluide corporel comprenant:
    l'appauvrissement de l'échantillon en hormones stéroïdes;
    l'isolement d'une fraction d'inhibiteur à base d'immunoglobuline à partir de l'échantillon appauvri en hormones stéroïdes; et
    tester ladite fraction d'inhibiteur à base d'immunoglobuline appauvri en hormones stéroïdes sur l'inhibition réversible par des hormones stéroïdes de la croissance de cellules sensibles aux hormones stéroïdes dans une population prédéterminée de cellules cultivées maintenues dans un milieu comprenant un fluide nutritif basal substantiellement dénué de Fe (III) non lié et contenant l'ion calcium dans des conditions de culture favorisant la croissance des cellules où les cellules sont sensibles aux hormones stéroïdes pour une prolifération in vivo lors d'une implantation dans un hôte approprié et une augmentation mesurable de l'inhibition de la croissance des cellules avec une augmentation de la concentration de fraction d'inhibiteur à base d'immunoglobuline, à une concentration définie d'hormone stéroïde dans le milieu, indique la quantité d'inhibiteur dans l'échantillon de fluide corporel.
  13. Procédé selon la revendication 11, dans lequel l'échantillon de fluide corporel est choisi dans le groupe constitué de sérum, de plasma, d'urine, de fluide séminal, de lait, de colostrum et de mucus.
  14. Modèle de culture de cellules in vitro pour prévoir un effet d'un stimulus défini sur la croissance de cellules cancéreuses sensibles aux hormones stéroïdes in vivo, comprenant: des cellules cancéreuses sensibles aux hormones stéroïdes maintenues dans un milieu comprenant un fluide nutritif basal substantiellement dénué de Fe (III) non lié et contenant l'ion calcium et contenant une quantité d'inhibiteur à base d'immunoglobuline réversible par des hormones stéroïdes choisie dans le groupe constitué de IgA, IgM et IgG suffisante pour arrêter la croissance de cellules cancéreuses en l'absence d'une quantité inversant l'inhibition d'hormone stéroïde.
  15. Modèle in vitro selon la revendication 13, dans lequel les cellules de culture sensibles aux hormones stéroïdes sont choisies dans le groupe constitué de MTW9/PL2 (cancer mammaire de rat), T47D (carcinome du sein humain), MCF-7 (carcinome du sein humain), MCF-7A (carcinome du sein humain), MCF-7K (carcinome du sein humain), LNCaP (carcinome prostatique humain), ZR-75-I (carcinome prostatique humain), H-30I (tumeur du rein de hamster syrien), GHI et GH3 (tumeur pituitaire de rat), GH4C1 (tumeur pituitaire de rat) et HT-29 (cancer du côlon humain).
EP10184646.7A 2000-05-10 2001-05-10 Compositions et procédés pour le diagnostic, le traitement et la prévention des cancers répondant à l'hormone de croissance Expired - Lifetime EP2394659B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US20331400P 2000-05-10 2000-05-10
US20834800P 2000-05-31 2000-05-31
US20811100P 2000-05-31 2000-05-31
US22907100P 2000-08-30 2000-08-30
US23127300P 2000-09-08 2000-09-08
EP01948216A EP1328293B1 (fr) 2000-05-10 2001-05-10 Compositions et procedes permettant de demontrer la regulation du systeme immunitaire secretoire de la croissance de cellules cancereuses sensibles aux hormones steroides

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP01948216A Division EP1328293B1 (fr) 2000-05-10 2001-05-10 Compositions et procedes permettant de demontrer la regulation du systeme immunitaire secretoire de la croissance de cellules cancereuses sensibles aux hormones steroides
EP01948216.5 Division 2001-05-10

Publications (2)

Publication Number Publication Date
EP2394659A1 EP2394659A1 (fr) 2011-12-14
EP2394659B1 true EP2394659B1 (fr) 2014-01-22

Family

ID=27539481

Family Applications (5)

Application Number Title Priority Date Filing Date
EP10185003A Ceased EP2394660A1 (fr) 2000-05-10 2001-05-10 Compositions et procédés pour le diagnostic, le traitement et la prévention des cancers répondant à l'hormone de croissance
EP01952116A Expired - Lifetime EP1366366B1 (fr) 2000-05-10 2001-05-10 Compositions et methodes de diagnostic, de traitement et de prevention de cancers sensibles aux hormones steroides
EP10184776A Withdrawn EP2359857A3 (fr) 2000-05-10 2001-05-10 Compositions et procédés pour le diagnostic, le traitement et la prévention des cancers répondant à l'hormone de croissance
EP10184646.7A Expired - Lifetime EP2394659B1 (fr) 2000-05-10 2001-05-10 Compositions et procédés pour le diagnostic, le traitement et la prévention des cancers répondant à l'hormone de croissance
EP01948216A Expired - Lifetime EP1328293B1 (fr) 2000-05-10 2001-05-10 Compositions et procedes permettant de demontrer la regulation du systeme immunitaire secretoire de la croissance de cellules cancereuses sensibles aux hormones steroides

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EP10185003A Ceased EP2394660A1 (fr) 2000-05-10 2001-05-10 Compositions et procédés pour le diagnostic, le traitement et la prévention des cancers répondant à l'hormone de croissance
EP01952116A Expired - Lifetime EP1366366B1 (fr) 2000-05-10 2001-05-10 Compositions et methodes de diagnostic, de traitement et de prevention de cancers sensibles aux hormones steroides
EP10184776A Withdrawn EP2359857A3 (fr) 2000-05-10 2001-05-10 Compositions et procédés pour le diagnostic, le traitement et la prévention des cancers répondant à l'hormone de croissance

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01948216A Expired - Lifetime EP1328293B1 (fr) 2000-05-10 2001-05-10 Compositions et procedes permettant de demontrer la regulation du systeme immunitaire secretoire de la croissance de cellules cancereuses sensibles aux hormones steroides

Country Status (8)

Country Link
US (4) US7947275B2 (fr)
EP (5) EP2394660A1 (fr)
AT (2) ATE485520T1 (fr)
AU (2) AU2001269690A1 (fr)
CA (2) CA2409765A1 (fr)
DE (1) DE60143320D1 (fr)
MX (2) MXPA02011093A (fr)
WO (2) WO2001086307A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863011B2 (en) * 2000-05-10 2011-01-04 Signe Biopharma, Inc. Screening method for predicting susceptibility to breast cancer
US20030072812A1 (en) * 2001-05-10 2003-04-17 Sirbasku David A Breast cancer eradication program
US8119138B2 (en) * 2000-05-10 2012-02-21 Signe Biopharma Inc. Anti-estrogen and immune modulator combinations for treating breast cancer
MXPA02011093A (es) 2000-05-10 2004-08-19 David A Sirbasku Composiciones y metodos para el diagnostico, tratamiento y prevencion de canceres que responden a la hormona esteroidea.
CA2451770A1 (fr) * 2001-06-28 2003-01-09 Entelos, Inc. Methode et systeme de modelisation informatique d'une reponse immunitaire adaptative
AU2002343714A1 (en) 2001-11-13 2003-05-26 David A. Sirbasku Breast cancer eradication program
EP1515748A4 (fr) * 2001-11-14 2006-04-12 David A Sirbasku Combinaisons d'antioestrogenes et d'immunomudulateurs pour traiter le cancer du sein
EP1490502B1 (fr) * 2001-11-14 2013-01-09 Signe BioPharma Inc. Methode de depistage permettant d'evaluer une predisposition au cancer du sein
US7364846B2 (en) * 2002-10-11 2008-04-29 Molecular Devices Corporation Gene expression profiling from FFPE samples
EP2471924A1 (fr) * 2004-05-28 2012-07-04 Asuragen, INC. Procédés et compositions impliquant du microARN
EP2302055B1 (fr) 2004-11-12 2014-08-27 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
WO2008073922A2 (fr) * 2006-12-08 2008-06-19 Asuragen, Inc. Fonctions et cibles de microarn let-7
ATE552334T1 (de) * 2005-09-13 2012-04-15 Takara Bio Inc Serumfreies medium zur herstellung von retroviralen vektoren
AU2007299748A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention
EP2487240B1 (fr) * 2006-09-19 2016-11-16 Interpace Diagnostics, LLC Micro ARN différemment exprimés dans des maladies pancréatiques et leurs utilisations
WO2008073915A2 (fr) * 2006-12-08 2008-06-19 Asuragen, Inc. Microarn exprimés de manière différentielle en cas de leucémie et leurs utilisations
EP2104735A2 (fr) * 2006-12-08 2009-09-30 Asuragen, INC. Gènes et voies génétiques régulés par mir-21 utilisés en tant que cibles pour une intervention thérapeutique
US8709413B2 (en) * 2006-12-13 2014-04-29 Michael R. Simon Treatment of celiac disease with IgA
CA2671270A1 (fr) * 2006-12-29 2008-07-17 Asuragen, Inc. Genes et voies regules par mir-16 utiles comme cibles pour intervention therapeutique
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US8015145B2 (en) * 2007-06-05 2011-09-06 Siemens Medical Solutions Usa, Inc. System for providing healthcare operation specific user interface display images
WO2008154333A2 (fr) * 2007-06-08 2008-12-18 Asuragen, Inc. Gènes et chemins régulés par mir-34 en tant que cibles pour une intervention thérapeutique
EP2198050A1 (fr) 2007-09-14 2010-06-23 Asuragen, INC. Microarn exprimés de manière différentielle dans le cancer du col de l'utérus et leurs utilisations
WO2009052386A1 (fr) * 2007-10-18 2009-04-23 Asuragen, Inc. Micro arn exprimés différentiellement dans des maladies pulmonaires et leurs utilisations
WO2009070805A2 (fr) * 2007-12-01 2009-06-04 Asuragen, Inc. Gènes régulés par le mir-124 et cheminements servant de cibles pour une intervention thérapeutique
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20090193338A1 (en) * 2008-01-28 2009-07-30 Trevor Fiatal Reducing network and battery consumption during content delivery and playback
EP2260110B1 (fr) * 2008-02-08 2014-11-12 Asuragen, INC. Micro arn (mirna) exprimés différentiellement dans des noeuds lymphoïdes prélevés chez des patients atteints d'un cancer
EP2268832A2 (fr) * 2008-03-06 2011-01-05 Asuragen, INC. Marqueurs microrna pour la récurrence d un cancer colorectal
WO2009154835A2 (fr) * 2008-03-26 2009-12-23 Asuragen, Inc. Compositions et procédés liés à mir-16 et à la thérapie contre le cancer de la prostate
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
JP2012530133A (ja) * 2009-06-16 2012-11-29 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 時間の経った赤血球の輸血に伴う副作用を改善するための方法
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
WO2013040251A2 (fr) 2011-09-13 2013-03-21 Asurgen, Inc. Méthodes et compositions incluant mir-135b, permettant de faire la distinction entre un cancer du pancréas et une maladie pancréatique bénigne
EP3049514B1 (fr) * 2013-09-24 2019-11-20 University Of Miami Milieux de culture cellulaire
DK3126383T3 (en) 2014-04-03 2019-04-01 Igm Biosciences Inc MODIFIED J-CHAIN
DK3265575T3 (da) 2015-03-04 2021-05-31 Igm Biosciences Inc Cd20-bindende molekyler og anvendelser deraf
DK3356401T3 (da) * 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393071A (en) 1975-03-17 1983-07-12 Naoharu Fujii Method of treating gastric, mammary, lung and uterus tumors
FR2558373B1 (fr) 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US4683200A (en) 1984-05-17 1987-07-28 Setsuo Hirohashi Monoclonal antibody to human cancer antigen and method for producing same
GB8607137D0 (en) 1986-03-21 1986-04-30 Efamol Ltd Compositions
US5135849A (en) 1986-04-17 1992-08-04 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of androgens
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
GB8628104D0 (en) 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
US5980896A (en) 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
DE3927112C1 (fr) * 1989-08-17 1990-10-25 Biotest Pharma Gmbh, 6072 Dreieich, De
CN1057785A (zh) * 1990-04-16 1992-01-15 哈佛大学校长及研究员协会 合成多聚免疫球蛋白受体，受体-抗体复合物，生产及应用
RU1837891C (ru) 1991-01-31 1993-08-30 Keshelava Viktor V Способ получени противоопухолевого средства
WO1992013500A1 (fr) 1991-02-08 1992-08-20 Surgical Innovations, Inc. Appareil et procede de reparation d'hernies inguinales
US6200547B1 (en) 1994-01-26 2001-03-13 Ferx Incorporated Magnetically responsive compositions for carrying biologically active substances and methods of production and use
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5641863A (en) 1993-09-30 1997-06-24 University Of Pennsylvania Chimeric IgG Fc receptors
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
JPH07238036A (ja) * 1994-02-28 1995-09-12 Green Cross Corp:The 静注用グロブリン液状組成物のグロブリン二量体増加抑制方法
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
US5866323A (en) * 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
CA2224115A1 (fr) 1995-06-07 1996-12-19 Washington University Complexes metalliques polydentes et leurs procedes de preparation et d'utilisation
WO1997046715A1 (fr) * 1996-06-03 1997-12-11 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Polymorphisme du recepteur fc
EP0920490A2 (fr) 1996-07-25 1999-06-09 Genzyme Corporation Formulations de milieux de culture de chondrocytes et procedes de culture
EP2221361A3 (fr) * 1996-08-30 2011-02-09 Life Technologies Corporation Méthode de production d'un polypeptide in vitro dans une cellule de mammifère dans un milieu de culture sans sérum and sans protéines
JP2001510690A (ja) * 1997-07-28 2001-08-07 エール ユニヴァーシティ ヒトエストロゲン受容体β
US6020161A (en) 1997-08-19 2000-02-01 Smithkline Beecham Corporation PIGR-1, a member of immunoglobulin gene superfamily
JP2002507387A (ja) 1997-12-24 2002-03-12 コリクサ コーポレイション 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
WO2000005403A1 (fr) * 1998-07-24 2000-02-03 Uab Research Foundation POLYMORPHISME GENETIQUE DANS LE RECEPTEUR DE IgA
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6844189B1 (en) 1998-11-06 2005-01-18 Myriad Genetics, Inc. Chromosome 17P-linked prostate cancer susceptibility gene
JP2003532378A (ja) 1999-11-29 2003-11-05 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク リンパ腫／黒色腫の発症に関与する新規Ｆｃ受容体型黒色腫をコードする５つの新規遺伝子の単離
EP1261371A4 (fr) 2000-02-25 2005-04-13 Univ California Therapie dirigee sur le recepteur membranaire des oestrogenes, dans le cancer du sein
US6763307B2 (en) 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
EP1268555A2 (fr) 2000-03-27 2003-01-02 The Regents of The University of California Ligands diriges contre le composant non secreteur et la region du filament d'un pigr et procedes d'utilisation associes
MXPA02011093A (es) 2000-05-10 2004-08-19 David A Sirbasku Composiciones y metodos para el diagnostico, tratamiento y prevencion de canceres que responden a la hormona esteroidea.
US8119138B2 (en) 2000-05-10 2012-02-21 Signe Biopharma Inc. Anti-estrogen and immune modulator combinations for treating breast cancer
AU2002343714A1 (en) 2001-11-13 2003-05-26 David A. Sirbasku Breast cancer eradication program
EP1490502B1 (fr) 2001-11-14 2013-01-09 Signe BioPharma Inc. Methode de depistage permettant d'evaluer une predisposition au cancer du sein

Also Published As

Publication number Publication date
US20120028258A1 (en) 2012-02-02
DE60143320D1 (de) 2010-12-02
EP1366366A2 (fr) 2003-12-03
ATE545433T1 (de) 2012-03-15
US20020012954A1 (en) 2002-01-31
EP2359857A2 (fr) 2011-08-24
EP1328293A2 (fr) 2003-07-23
CA2409150A1 (fr) 2001-11-15
US7947463B2 (en) 2011-05-24
MXPA02011092A (es) 2004-08-19
EP1328293B1 (fr) 2012-02-15
ATE485520T1 (de) 2010-11-15
MXPA02011093A (es) 2004-08-19
CA2409765A1 (fr) 2001-11-15
WO2001086307A2 (fr) 2001-11-15
EP1366366B1 (fr) 2010-10-20
AU2001272908A1 (en) 2001-11-20
EP2394660A1 (fr) 2011-12-14
WO2001085210A3 (fr) 2003-04-17
US20120115161A1 (en) 2012-05-10
US8563249B2 (en) 2013-10-22
EP2359857A3 (fr) 2012-02-22
AU2001269690A1 (en) 2001-11-20
WO2001086307A3 (fr) 2003-10-02
US7947275B2 (en) 2011-05-24
US20020006630A1 (en) 2002-01-17
EP2394659A1 (fr) 2011-12-14
WO2001085210A2 (fr) 2001-11-15

Similar Documents

Publication Publication Date Title
EP2394659B1 (fr) Compositions et procédés pour le diagnostic, le traitement et la prévention des cancers répondant à l'hormone de croissance
Kumpel et al. Placental immunology and maternal alloimmune responses
Genbacev et al. Maternal smoking inhibits early human cytotrophoblast differentiation
US20120121620A1 (en) Anti-estrogen and immune modulator combinations for treating breast cancer
BRPI0707529A2 (pt) métodos para modulação do teor de manose de proteìnas recombinantes
CA2265516C (fr) Methode pour detecter les effets secondaires des contraceptifs et des substituts ou supplements d'oestrogenes et/ou de progesterone
Chrousos et al. The squirrel monkey: receptor-mediated end-organ resistance to progesterone?
Tchernitchin et al. Degranulatory action of estradiol on blood eosinophil leukocytes in vivo and in vitro
Pietras et al. Estrogen-induced membrane alterations and growth associated with proteinase activity in endometrial cells.
US5135849A (en) In-vitro methods for identifying compositions which are agonists and antagonists of androgens
CA2804977A1 (fr) Compositions et procedes permettant de demontrer la regulation du systeme immunitaire secretoire de la croissance de cellules cancereuses sensibles aux hormones steroides
Spicer et al. Concentrations of insulin-like growth factor-I in follicular fluid and blood plasma of mares during early and late oestrus
Schuffler et al. In vitro immunoglobulin allotype synthesis by spleen cells of heterozygous rabbits: Specific suppression by anti-allotype antibody
Fehl et al. Further indications of the multicomponent nature of the acrosome reaction‐inducing substance of human follicular fluid
Abrahams et al. Inhibition of Human Polymorphonuclear Cell Oxidative Burst by 17‐β‐estradiol and 2, 3, 7, 8‐tetrachlorodibenzo‐p‐dioxin
Babalola et al. Sex steroid changes in porcine cystic ovarian disease
Foong et al. Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating hormone
LU et al. Regulation of rat pancreatic glucocorticoid receptors by thyroxine during development
Kumpel et al. Transcytosis of IgG anti‐D by human term trophoblast cells in culture
Finkelstein et al. Department of Endocrinology, Hebrew University-Hadassah
Mayer et al. Glucocorticoid binding in cytosol of cultured rat myoblasts
Giusti et al. Relevance of Maternal Thyroid Autoantibodies on the Development of Congenital Hypothyroidism
Yamada et al. A monoclonal antibody, HCL-2, raised against human luteal cells reacts with apolipoprotein-B and detects the uptake of low density lipoprotein by luteinizing granulosa cells.
EP1515748A2 (fr) Combinaisons d'antioestrogenes et d'immunomudulateurs pour traiter le cancer du sein
Kumar et al. Immunohistochemical analysis of the stage-specific expression of Ia antigens in the rat mammary gland during pregnancy and lactation

Legal Events

Date Code Title Description
AC Divisional application: reference to earlier application

Ref document number: 1328293

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120424

17Q First examination report despatched

Effective date: 20120625

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1162333

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20131007

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1328293

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 650445

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60148577

Country of ref document: DE

Effective date: 20140306

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140122

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 650445

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140122

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140122

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140122

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140122

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140522

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140122

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140122

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60148577

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140122

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60148577

Country of ref document: DE

26N No opposition filed

Effective date: 20141023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140510

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140531

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140122

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60148577

Country of ref document: DE

Effective date: 20141023

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150130

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60148577

Country of ref document: DE

Effective date: 20141202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140510

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140510

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140122

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1162333

Country of ref document: HK